The Immunotherapy Drugs Market is predicted to grow during the research period from 2017 to 2025.
What Are the Driving Factors for Immunotherapy Drugs Market?
- Growing number of patients diagnosed with various types of cancer
- Growing number of patients diagnosed with various types of autoimmune diseases
- Increasing demand for immunotherapy drugs for patients who have undergone a transplant surgery
|By Types||MAB, Interleukins, Interferons, Colony Stimulating factors, Therapeutic Vaccines, Checkpoint Inhibitors and others|
|By Indications||Anti-Cancer Drugs, Drugs for Autoimmune Diseases, Allergies, Organ Transplant, Hepatitis-C and others|
|By Regions||North America, Europe, Asia-Pacific, Middle East & Africa, South America|
|The U.S.||Bristol-Myers Squibb, Merck & Co., Inc., Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson & others|
|Switzerland||F. Hoffmann-La Roche Ltd., Novartis AG. & others|
|The U.K.||GlaxoSmithKline Plc, Astra Zeneca Plc & others|
|Russia||Amgen, Inc. & others|
Why Buy this Report?
- This report provides in-depth analysis of market determinant factors.
- This report analyzes market dynamics for each segment (such as Types, Indications, Regions ).
- This report provides 8 years forecast by analyzing push and pull factors affecting the dynamics of the market.
- This report provides application level cross-sectional analysis for each product type.
- This report provides regional level pricing trend analysis.
- This report acts as business decision support system by analyzing key trends in each market segment.
- This report provides insights regarding business strategies of leading market players.
Immunotherapy Drugs Market - Introduction
The global immunotherapy drugs market is expected to expand at a very fast growth rate in coming years. Immunotherapy drugs market is segmented on the basis of types, indications, and geography. Immunotherapy drugs are drugs which utilize the body’s natural immune system to fight a disease or to protect the body from any adverse effects of an ongoing treatment, by either stimulating the naturally present defense mechanism of the body or by restoring the depleted immune system of the body. Immunotherapy drugs are most prevalent for the treatment of various cancers and autoimmune diseases. They are also widely used by patients who have undergone a transplant operation. The primary reason for the growth of the immunotherapy drugs products market can be attributed to the growing number of cancer patients globally.
|Base Year of Estimation||2016|
|Value Estimation Year||2017|
|Forecast Period||2017 - 2025|
|Market Segmentations||By Types, Indications, Regions|
|Regional Scope||North America, Europe, Asia-Pacific, Middle East & Africa, South America|
|Report Coverage||Market Dynamics, Segmentation Overview and Competitive Landscape of the market|
As of 2016, growth in demand for immunotherapy drugs is driven by factors including growth in the number of patients diagnosed with various types of cancer, growth in the number of patients diagnosed with various types of autoimmune diseases and growing demand for immunotherapy drugs for patients who have undergone a transplant surgery. The number of persons, diagnosed with various types of cancers, has been growing at a significant pace for the past few years. As per the World Health Organization’s data, approximately 8.8 million persons died from cancer in 2015 while approximately 14 million persons were diagnosed to have cancer in 2012. Immunotherapy drugs are generally used as anti-cancer medicines or as an adjuvant therapy. Rituximab and bevacizumab can be cited as examples of the same. Hence, the growing numbers of cancer patients globally, are expected to act as a push factor for the immunotherapy drugs market.
Additionally, immunotherapy drugs are also prescribed and administered for autoimmune diseases, such as rheumatoid arthritis. With the growth in world population, there has been a significant growth in the number of patients suffering from autoimmune diseases. Such growth in autoimmune disease patients has also led to increased usage of immunotherapy drugs, thus again positively impacting the growth of the market. Furthermore, immunotherapy drugs are required by all patients who have undergone organ transplants, to prevent the rejection of the donor’s organ by the receiver’s body. Hence such patients are required to consume these immunotherapy drugs, also known as an immunosuppressant, for the rest of their life. This has further boosted the growth of the immunotherapy drugs market.
However, the relatively higher cost has been restraining the growth of the market in several emerging economies, where there is a presence of a large patient pool for these drugs. Also, concerns of side-effects of immunotherapy drugs have also been restraining the growth of the market. Lack of suitable alternatives and prescription of these drugs for various other indications, including orphan diseases, can be expected to provide good future growth opportunities for the market of immunotherapy drugs.
The immunotherapy drugs market, on the basis of types, has been segmented into monoclonal antibody (MAB), interleukins, interferons, colony stimulating factors (CSFs) and others. Others segment covers immunotherapy drug types such as therapeutic vaccines, checkpoint inhibitors etc. MAB was the largest individual segment in 2016, globally, owing to their applications in a wide range of indications. Checkpoint inhibitors were the fastest growing segment in 2016. On the basis of indications, the market for immunotherapy drugs has been segmented into anti-cancer drugs, drugs for autoimmune diseases and others. Others segment covers indications such as allergies, organ transplant, and Hepatitis-C among others.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, Middle East & Africa (MEA) and South America. In terms of revenue, North America held the largest share of the immunotherapy drugs market, followed by Europe.Asia-Pacific is expected to become the largest market for immunotherapy drugs by end of 2025.
Leading players operating in the immunotherapy drugs market are Bristol-Myers Squibb (The U.S.), Merck & Co., Inc. (The U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (The U.S.), GlaxoSmithKline Plc (The U.K.), Amgen, Inc. (Russia), Novartis AG. (Switzerland), Eli Lilly and Company (The U.S.) Astra Zeneca Plc (The U.K.) and Johnson & Johnson (The U.S.) among others. As compared to North America and Europe, the concentration of immunotherapy drug producers is relatively low in countries from Asia-Pacific, Middle East and Africa (MEA) and South America.
|Related Upcoming Report Titles|
|Get Free Samples for Market Research Reports. The privacy and security of your shared information are very important to us. Our website is secure and your personal details are safe.|